Lachesis Biosciences is a development company focused on nasal spray and nasal absorption technology. Lachesis Biosciences clinical-stage, Rivastigmine Nasal Spray product candidate is for the treatment of dementia symptoms associated with Alzheimer’s and Parkinson’s diseases.
Lachesis Biosciences Limited are pleased to provide a Prospectus to raise up to $6,000,000 by an Offer to the public comprising: Offer of 5,000,000 New Shares at an issue price of $1.00 each totaling $5,000,000; and Oversubscriptions of up to a maximum of $1,000,000.
